Dr. Drew Hissong


Dr. Drew Hissong

  • P 202-721-8237
  • F 202-721-8250

Drew’s practice at Wenderoth focuses on the preparation and prosecution of biotechnology, chemical, and pharmaceutical patent applications. Drew has significant experience in client counseling and in the preparation of freedom to operate, patentability, validity and non-infringement opinions. In addition to serving domestic and international companies, Drew's clients include public and private universities. 

Prior to joining the firm, Drew Hissong spent over 15 years in private practice where he focused on intellectual property. While in law school, he served as a law clerk and summer associate. 

Drew’s practice encompasses a wide range of technologies including:

  • Polynucleotides
  • Assay Systems
  • Mechanisms of Signal Transduction
  • Inorganic and Organic Chemistry
  • Molecular Tools such as Vectors and Promoters
  • Modulators of Apoptosis 
  • Anti-sense RNA
  • Stem Cells
  • Hyridomas and Antibodies
  • Bacterial Cell Lines
  • Antimicrobials
  • Bacteriophage
  • Pharmaceuticals
  • Food Products
  • Cytotoxic Agents

Before his law career and while working on his doctorate, Drew served as a research assistant at the University of North Carolina at Chapel Hill (UNC), focusing on molecular biology with an emphasis on growth factor maturation and processing. He also taught microbiology to undergraduate students while at UNC.

  • Instructor on Claims Drafting, AIPLA Boot Camp for New Associates, August 2009
  • Instructor on Claims Drafting, AIPLA Boot Camp for New Associates, August 2007
  • From the Laboratory to the Court Room: Careers for Scientists in Patent Law,
    University of North Carolina-Chapel Hill, Chapel Hill Nc, April 21, 2005
  • Utility Guidelines, Homology Claims and Anti-Sense Molecule Claims
    Korean Intellectual Property Office, Daejeon, Republic of Korea, February 11, 2004
  • Changes to the Hatch-Waxman Act as Part of the Medicare Reform Act of 2003
    Korean Drug Research Association, Seoul National University, Seoul,
    Republic of Korea, February 10, 2004
  • Est Patents After Fisher: Decision Leaves Door Open for Proving their Utility. The
    Patent Lawyer 2(3):18-19 (2005).
  • The Carboxy-Terminal Valine Residues of Protgfa are Required for its Efficient
    Maturation and Intracellular Routing. Mol. Biol. Cell 8:1619-1631 (1997)
  • Transcriptional and Post-Transcriptional Induction of The Tgfα Gene in Transformed Rat Liver Epithelial Cells. Oncogene 12:1991 (1996)
  • Transforming Growth Factor α:Expression, Regulation, And Biological Activities.
    Pharmacological Reviews 47:51 (1995)